Who are Paparid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HEXOCYCLIUM, Kemadrine, Incruse, scopolamin, Salagen, UMEC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bietamiverine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Paparid — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paparid (BIETAMIVERINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: bietamiverine. Area: Other.

phase 2 bietamiverine Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 Other Small molecule Live · refreshed every 30 min

Target snapshot

Paparid (BIETAMIVERINE). Paparid works by blocking the M3 receptor, which helps to reduce smooth muscle contraction and glandular secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paparid TARGET	BIETAMIVERINE		phase 2	bietamiverine	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
HEXOCYCLIUM	HEXOCYCLIUM	AbbVie	marketed	hexocyclium	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3	1982-01-01
Kemadrine	PROCYCLIDINE		marketed		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3	1955-01-01
Incruse	Incruse	Fundacio Privada Mon Clinic Barcelona	marketed		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
scopolamin	scopolamin	University Hospital, Angers	marketed		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Salagen	Salagen	Alberta Health services	marketed		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
UMEC	UMEC	Glaxo Grp England	marketed		Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (bietamiverine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paparid — Competitive Intelligence Brief. https://druglandscape.com/ci/bietamiverine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing